Prabha Sridevan, the former chairperson of India’s Intellectual Property Appellate Board, says that just as Indian companies must obey American laws when selling their wares in the US, international pharmaceutical companies must similarly comply with Indian laws if they wish to do business in the world’s second most populous market
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
The model covers court-guided settlements, submissions-led determination of infringement and validity issues, and provides leeway for the court to determine a FRAND rate during negotiations